LQTS probands with compound mutations were significantly more likely to experience cardiac arrest compared to those with one or no identified mutation (56% vs 27%; OR 3.5; 95% CI 1.2 to 9.9; P<0.01).
Observational (n=252)
Effect estimate: OR 3.5 (95% CI 1.2 to 9.9)
Absolute Event Rate: 56% vs 27%
p-value: p=<0.01
Background— Long QT syndrome (LQTS) predisposes affected individuals to sudden death from cardiac arrhythmias. Although most LQTS individuals do not have cardiac events, significant phenotypic variability exists within families. Probands can be very symptomatic. The mechanism of this phenotypic variability is not understood. Methods and Results— Genetic analyses of KVLQT1, HERG , KCNE1 , KCNE2 , and SCN5A detected compound mutations in 20 of 252 LQTS probands (7.9%). Carriers of 2 mutations had longer QTc intervals (527±54 versus 489±44 ms; P <0.001); all had experienced cardiac events (20 of 20 100% versus 128 of 178 72%; P <0.01) and were 3.5-fold more likely to have cardiac arrest (9 of 16 56% versus 45 of 167 27%; P <0.01; OR, 3.5; 95% CI, 1.2 to 9.9) compared with probands with 1 or no identified mutation. Two-microelectrode voltage clamp of Xenopus oocytes was used to characterize the properties of variant slow delayed rectifier potassium ( I Ks ) channels identified in 7 of the probands. When wild-type and variant subunits were coexpressed in appropriate ratios to mimic the genotype of the proband, the reduction in I Ks density was equivalent to the additive effects of the single mutations. Conclusions— LQTS-associated compound mutations cause a severe phenotype and are more common than expected. Individuals with compound mutations need to be identified, and their management should be tailored to their increased risk for arrhythmias.
Westenskow et al. (Tue,) conducted a observational in Long QT syndrome (LQTS) (n=252). Compound mutations vs. 1 or no identified mutation was evaluated on Cardiac arrest (OR 3.5, 95% CI 1.2 to 9.9, p=<0.01). LQTS probands with compound mutations were significantly more likely to experience cardiac arrest compared to those with one or no identified mutation (56% vs 27%; OR 3.5; 95% CI 1.2 to 9.9; P<0.01).